ZG005 + donafenib

ZG005 + donafenib is a combination therapy undergoing clinical evaluation for the treatment of advanced hepatocellular carcinoma. - **ZG005** is an investigational biologic agent (details on specific mechanism and molecular modality are currently unavailable from public data). - **Donafenib** is a deuterated derivative of sorafenib, functioning as an oral multikinase inhibitor. It blocks the activity of multiple receptor kinases, including Raf kinase, vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR), disrupting Raf/MEK/ERK signaling and thereby inhibiting tumor cell proliferation and angiogenesis. Donafenib demonstrates improved tolerability and metabolic stability compared to sorafenib due to the incorporation of deuterium. The combination is being studied in a randomized, open-label Phase 1/2 setting for first-line treatment of patients with unresectable or advanced hepatocellular carcinoma[1][3][5][6][7].

Brand names

Zepsun

Other names

ZG005 + donafenibDonafenib Tosilate TabletsZepsunSorafenib-d3Sorafenib-d-3Sorafenib-d 3CM-4307CM4307CM 4307